Tirzepatide vs Semaglutide: How to Choose With Your Doctor

People comparing tirzepatide vs semaglutide often end up asking the same question: which one is better? A more useful question is which one fits your health history, your goals, your dosing needs, and what you can actually get. Both are once-weekly injections used for weight management, and both have labels for type 2 diabetes in certain products.

The two drugs work through different receptors. Tirzepatide acts on both GIP and GLP-1 receptors. Semaglutide acts on GLP-1 receptors only. That difference is real, but it doesn't automatically mean a better result for you. Your prescriber weighs it alongside everything else in your history.

This post supports your conversation with your prescriber. It doesn't replace their evaluation. Keeping notes between visits can make that conversation easier, and some readers use TirzeBlog to organize what they want to ask.

What the approved labels say

Labels differ by country, so start with the document for your product. In the United States, tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Zepbound also carries an indication for moderate to severe obstructive sleep apnea in adults with obesity. Semaglutide comes in several brands. Ozempic is labeled for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus is the oral form for type 2 diabetes. Wegovy also carries a cardiovascular risk reduction indication.

Brazil works differently. Anvisa decides which products are registered and what indications they carry, and those can differ from the US labels. Read the bula that comes with your package, and check the current registration for the exact brand and presentation your prescriber has in mind.

What the head-to-head evidence shows

For a long time, most comparisons were indirect. Researchers lined up results from separate trials with different populations, durations, and designs. That helps form hypotheses, but it can't show how two drugs perform side by side.

SURMOUNT-5 changed that. It was a randomized trial that compared tirzepatide directly with semaglutide over 72 weeks, and it was published in the New England Journal of Medicine in 2025. The exact percentage weight change and discontinuation figures are in the paper, so check them there rather than in secondhand summaries.

Averages hide a lot. Some people lose a large amount of weight, others lose less, and some stop because of side effects. A trial average describes a group, not you. Side effects and adherence matter as much as the scale, because a medicine you can't keep taking won't help much.

The SELECT trial is the basis for Wegovy's cardiovascular indication. It studied adults with overweight or obesity and established cardiovascular disease, and it compared semaglutide with placebo. Those findings describe that study population. They don't tell you which drug suits your heart history.

Clinical factors to bring to your doctor

Dose range is an early practical difference. Tirzepatide starts at 2.5 mg weekly and can go up to 15 mg. Wegovy starts at 0.25 mg and goes up to 2.4 mg. Ozempic goes up to 2 mg. Dose increases are spaced about four weeks apart on these labels, so the path to your dose matters as much as the final number. Confirm current maximums with your prescriber, since labels get updated.

Your conditions shape the choice. Mention type 2 diabetes, cardiovascular disease, sleep apnea, kidney disease, gallbladder disease, any history of pancreatitis, and diabetic retinopathy. The semaglutide label includes a caution about rapid blood sugar lowering and retinopathy complications in people with type 2 diabetes, so tell your doctor about any eye problems.

Both drugs carry a boxed warning about thyroid C-cell tumors. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Share relevant family history, even if it feels distant.

Pregnancy planning matters too. Both labels say to stop before pregnancy, but the timing is specific to each product. Ask your prescriber for the exact window rather than borrowing a number from another drug. The same goes for oral contraceptives. Both medicines slow gastric emptying. Check the section of your product's label that covers oral medicines and contraception, and ask about dose increases in particular, since that's when the advice matters most.

Access, cost, and supply

In the United States, coverage for weight management depends on your plan and the specific product. The same prescription can be covered for one person and not another. Manufacturers offer self-pay programs and cash prices, but terms change, so confirm current details with your pharmacy and insurer.

In Brazil, pharmacy prices vary a lot from store to store, and prescription requirements depend on the product. Before your first fill, confirm that the exact product and presentation you're buying is registered with Anvisa.

Compounded versions need a clear warning. FDA has ended its shortage determinations for both tirzepatide and semaglutide, and compounded products aren't FDA-approved. Quality and dosing consistency can vary between compounders. If someone offers you one, ask your prescriber about it directly.

Preparing the conversation with your doctor

A little preparation makes the visit far more productive. Bring three things:

• A complete list of your medications and supplements


• Your weight and waist trend from the last six months, along with recent labs such as A1c, lipids, and kidney function


• Your history with any previous GLP-1 medicine

Then ask four questions. Which option fits my conditions? What starting dose and titration path makes sense for me? How will we measure my response beyond the scale? What do we do if side effects or coverage problems show up? Writing notes between visits helps you remember the answers, and TirzeBlog can be a handy reference for organizing questions as they come up.

Switching between the two drugs is a clinical decision. It depends on tolerance, goals, and access, and your doctor should guide the timing and any overlap.

Making the decision and setting checkpoints

Define success in more than one way. Track your weight trend, waist measurement, blood sugar markers if they apply to you, sleep quality, energy, and how the medicine fits into daily life. Schedule a review after the first few dose increases and again at about three months. Agree in advance on what would trigger a change.

Discuss stop criteria now, not in the middle of a hard week. Typical triggers include side effects you can't tolerate over time, no meaningful progress over an agreed period, or a new contraindication. When you review progress with your doctor, bring your notes and compare them with the targets you set together. For more context to take into that conversation, visit the TirzeBlog homepage.

FAQ

Is tirzepatide better than semaglutide for weight loss?

There's no general answer. SURMOUNT-5 compared the two directly over 72 weeks, but individual results vary widely. Your doctor can help you read the evidence in light of your own health history.

Can I switch from semaglutide to tirzepatide?

It may be possible, but switching is a clinical decision. Your prescriber should decide whether it makes sense and guide the timing based on your tolerance, goals, and access.

What should I ask about compounded versions?

Ask whether the product is FDA-approved or registered in your country, who made it, and how the dose is verified. Compounded products aren't FDA-approved, and quality and dosing consistency can vary.

Sources

• SURMOUNT-5: Tirzepatide versus Semaglutide for Weight Reduction in Adults with Obesity, New England Journal of Medicine (2025)
• SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, PubMed (PMID 37952131)
• DailyMed: Mounjaro (tirzepatide) prescribing information
• DailyMed: Zepbound (tirzepatide) prescribing information
• DailyMed: Ozempic (semaglutide) prescribing information
• DailyMed: Wegovy (semaglutide) prescribing information
• DailyMed: Rybelsus (semaglutide) prescribing information
• FDA: Drug Shortages
• FDA: Human Drug Compounding
• Anvisa: Consulta de medicamentos registrados